Lyc-55716: A novel small-molecule RORγ agonist immuno-oncology agent: Rationale for tumor selection and clinical evaluation of gastric and esophageal carcinoma in phase 2a expansion. The prognostic ...

Please provide your email address to receive an email when new articles are posted on . Palbociclib plus endocrine therapy was not associated with lowered quality of life among Black, indigenous and ...

Treatment Intensification With Either Fludarabine, AraC, G-CSF and Idarubicin, or Cladribine Plus Daunorubicin and AraC on the Basis of Residual Disease Status in Older Patients With AML: Results From ...

Please provide your email address to receive an email when new articles are posted on . The addition of palbociclib to anti-HER2 and endocrine therapy extended PFS by more than a year. The regimen ...

A recent trial sought to assess the effect of palbociclib on overall survival (OS) and the efficacy of subsequent therapy in patients with hormone receptor–positive (HR+), HER2-negative advanced ...

Palbociclib plus endocrine therapy did not improve overall survival in premenopausal patients with metastatic breast cancer. The regimen did improve progression-free survival compared with ...

Researchers showed the potential of combining 2 precision medicines to overcome treatment resistance. When palbociclib, a breast cancer drug, and crizotinib, a lung cancer drug, were used in ...

MUNICH -- Median survival in advanced hormone receptor-positive (HR+) improved by as much as 10 months in patients who received the cyclin-dependent kinase (CDK) 4/6 inhibitor palbociclib (Ibrance) in ...

Female patient on hospital bed. Palbociclib added to adjuvant endocrine therapy failed to improve iDFS. The following article features coverage from the 2021 San Antonio Breast Cancer Symposium. Click ...

NEW YORK--(BUSINESS WIRE)-- As announced today by the Austrian Breast & Colorectal Cancer Study Group and the Alliance Foundation Trials, LLC, Pfizer Inc. (NYSE: PFE) reports that following a ...

The phase 3 PADMA trial demonstrated that first-line treatment with palbociclib plus endocrine therapy (ET) significantly improves outcomes compared with standard mono chemotherapy in patients with ...